Clinical outcomes in a primary-level non-communicable disease programme for Syrian refugees and the host population in Jordan: A cohort analysis using routine data.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
04
10
2019
accepted:
13
11
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
7
5
2021
Statut:
epublish
Résumé
Little is known about the content or quality of non-communicable disease (NCD) care in humanitarian settings. Since 2014, Médecins Sans Frontières (MSF) has provided primary-level NCD services in Irbid, Jordan, targeting Syrian refugees and vulnerable Jordanians who struggle to access NCD care through the overburdened national health system. This retrospective cohort study explored programme and patient-level patterns in achievement of blood pressure and glycaemic control, patterns in treatment interruption, and the factors associated with these patterns. The MSF multidisciplinary, primary-level NCD programme provided facility-based care for cardiovascular disease, diabetes, and chronic respiratory disease using context-adapted guidelines and generic medications. Generalist physicians managed patients with the support of family medicine specialists, nurses, health educators, pharmacists, and psychosocial and home care teams. Among the 5,045 patients enrolled between December 2014 and December 2017, 4,044 eligible adult patients were included in our analysis, of whom 72% (2,913) had hypertension and 63% (2,546) had type II diabetes. Using visits as the unit of analysis, we plotted the following on a monthly basis: mean blood pressure among hypertensive patients, mean fasting blood glucose and HbA1c among type II diabetic patients, the proportion of each group achieving control, mean days of delayed appointment attendance, and the proportion of patients experiencing a treatment interruption. Results are presented from programmatic and patient perspectives (using months since programme initiation and months since cohort entry/diagnosis, respectively). General linear mixed models explored factors associated with clinical control and with treatment interruption. Mean age was 58.5 years, and 60.1% (2,432) were women. Within the programme's first 6 months, mean systolic blood pressure decreased by 12.4 mm Hg from 143.9 mm Hg (95% CI 140.9 to 146.9) to 131.5 mm Hg (95% CI 130.2 to 132.9) among hypertensive patients, while fasting glucose improved by 1.12 mmol/l, from 10.75 mmol/l (95% CI 10.04 to 11.47) to 9.63 mmol/l (95% CI 9.22 to 10.04), among type II diabetic patients. The probability of achieving treatment target in a visit was 63%-75% by end of 2017, improving with programme maturation but with notable seasonable variation. The probability of experiencing a treatment interruption declined as the programme matured and with patients' length of time in the programme. Routine operational data proved useful in evaluating a humanitarian programme in a real-world setting, but were somewhat limited in terms of data quality and completeness. We used intermediate clinical outcomes proven to be strongly associated with hard clinical outcomes (such as death), since we had neither the data nor statistical power to measure hard outcomes. Good treatment outcomes and reasonable rates of treatment interruption were achieved in a multidisciplinary, primary-level NCD programme in Jordan. Our approach to using continuous programmatic data may be a feasible way for humanitarian organisations to account for the complex and dynamic nature of interventions in unstable humanitarian settings when undertaking routine monitoring and evaluation. We suggest that frequency of patient contact could be reduced without negatively impacting patient outcomes and that season should be taken into account in analysing programme performance.
Sections du résumé
BACKGROUND
Little is known about the content or quality of non-communicable disease (NCD) care in humanitarian settings. Since 2014, Médecins Sans Frontières (MSF) has provided primary-level NCD services in Irbid, Jordan, targeting Syrian refugees and vulnerable Jordanians who struggle to access NCD care through the overburdened national health system. This retrospective cohort study explored programme and patient-level patterns in achievement of blood pressure and glycaemic control, patterns in treatment interruption, and the factors associated with these patterns.
METHODS AND FINDINGS
The MSF multidisciplinary, primary-level NCD programme provided facility-based care for cardiovascular disease, diabetes, and chronic respiratory disease using context-adapted guidelines and generic medications. Generalist physicians managed patients with the support of family medicine specialists, nurses, health educators, pharmacists, and psychosocial and home care teams. Among the 5,045 patients enrolled between December 2014 and December 2017, 4,044 eligible adult patients were included in our analysis, of whom 72% (2,913) had hypertension and 63% (2,546) had type II diabetes. Using visits as the unit of analysis, we plotted the following on a monthly basis: mean blood pressure among hypertensive patients, mean fasting blood glucose and HbA1c among type II diabetic patients, the proportion of each group achieving control, mean days of delayed appointment attendance, and the proportion of patients experiencing a treatment interruption. Results are presented from programmatic and patient perspectives (using months since programme initiation and months since cohort entry/diagnosis, respectively). General linear mixed models explored factors associated with clinical control and with treatment interruption. Mean age was 58.5 years, and 60.1% (2,432) were women. Within the programme's first 6 months, mean systolic blood pressure decreased by 12.4 mm Hg from 143.9 mm Hg (95% CI 140.9 to 146.9) to 131.5 mm Hg (95% CI 130.2 to 132.9) among hypertensive patients, while fasting glucose improved by 1.12 mmol/l, from 10.75 mmol/l (95% CI 10.04 to 11.47) to 9.63 mmol/l (95% CI 9.22 to 10.04), among type II diabetic patients. The probability of achieving treatment target in a visit was 63%-75% by end of 2017, improving with programme maturation but with notable seasonable variation. The probability of experiencing a treatment interruption declined as the programme matured and with patients' length of time in the programme. Routine operational data proved useful in evaluating a humanitarian programme in a real-world setting, but were somewhat limited in terms of data quality and completeness. We used intermediate clinical outcomes proven to be strongly associated with hard clinical outcomes (such as death), since we had neither the data nor statistical power to measure hard outcomes.
CONCLUSIONS
Good treatment outcomes and reasonable rates of treatment interruption were achieved in a multidisciplinary, primary-level NCD programme in Jordan. Our approach to using continuous programmatic data may be a feasible way for humanitarian organisations to account for the complex and dynamic nature of interventions in unstable humanitarian settings when undertaking routine monitoring and evaluation. We suggest that frequency of patient contact could be reduced without negatively impacting patient outcomes and that season should be taken into account in analysing programme performance.
Identifiants
pubmed: 33428612
doi: 10.1371/journal.pmed.1003279
pii: PMEDICINE-D-19-03684
pmc: PMC7799772
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003279Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2016 Apr 13;11(4):e0150088
pubmed: 27073930
Confl Health. 2017 Sep 17;11:17
pubmed: 28932259
PLoS Med. 2016 Nov 8;13(11):e1002180
pubmed: 27824879
BMC Public Health. 2015 Oct 31;15:1097
pubmed: 26521231
Diabetes Care. 2016 Jan;39 Suppl 1:S23-35
pubmed: 26696676
Trans R Soc Trop Med Hyg. 2015 Jul;109(7):440-6
pubmed: 25997923
Trop Med Int Health. 2014 Feb;19(2):219-23
pubmed: 24341942
Confl Health. 2019 Apr 2;13:12
pubmed: 30976298
Blood Press Monit. 2007 Jun;12(3):195-203
pubmed: 17496471
BMJ. 2004 Jan 24;328(7433):204
pubmed: 14726370
Lancet Glob Health. 2018 Nov;6(11):e1196-e1252
pubmed: 30196093
Trop Med Int Health. 2008 Oct;13(10):1225-34
pubmed: 18937743
J Hypertens. 2012 Jul;30(7):1383-91
pubmed: 22688260
Trop Med Int Health. 2012 Sep;17(9):1163-70
pubmed: 22845700
Diabet Med. 2017 Feb;34(2):156-166
pubmed: 26996656
Heart. 2019 Sep;105(18):1382-1383
pubmed: 31154428
BMC Med. 2009 Jul 14;7:33
pubmed: 19602220
Health Policy Plan. 2020 Oct 1;35(8):931-940
pubmed: 32621490
PLoS Med. 2013;10(1):e1001377
pubmed: 23382655
Trop Med Int Health. 2014 Oct;19(10):1276-83
pubmed: 25039838
Lancet. 2010 Jan 23;375(9711):341-5
pubmed: 20109961
Clin Chem. 2007 May;53(5):897-901
pubmed: 17384010
PLoS One. 2015 Sep 25;10(9):e0138303
pubmed: 26406317
Trop Med Int Health. 2012 Dec;17(12):1569-76
pubmed: 23051859
BMC Fam Pract. 2017 Mar 23;18(1):46
pubmed: 28330453
Am J Public Health. 2015 Mar;105(3):431-7
pubmed: 25602898
Confl Health. 2016 Jun 01;10:12
pubmed: 27252775
Clin Diabetes. 2019 Jan;37(1):11-34
pubmed: 30705493
Confl Health. 2019 Mar 22;13:8
pubmed: 30949232
J Hum Hypertens. 2011 Apr;25(4):241-9
pubmed: 20445572
Confl Health. 2018 Jul 11;12:33
pubmed: 30008800
Confl Health. 2019 Jun 13;13:26
pubmed: 31210780
Arch Intern Med. 1990 Jul;150(7):1509-10
pubmed: 2369248
Br Med J (Clin Res Ed). 1982 Oct 2;285(6346):919-23
pubmed: 6811068